Treace Medical Concepts, Inc. TMCI
4.50
(0.04)
(0.88%)
as of 25 Sep
- Market cap
- $295.3M
- P/E
- 0.0×
Follow TMCI
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.26 | 0.42 | 0.73 | 1.95 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(55.11) | 11.96 | (19.31) | (46.88) | |
P/B ratio |
3.82 | 1.12 | 1.77 | 4.78 | |
Price to Tangible BV |
5.36 | 1.51 | 2.30 | 6.18 | |
EV/Sales |
1.32 | 0.44 | 0.77 | 1.93 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(18.56) | (7.09) | (10.23) | (34.85) | |
EV/FCF |
(10.80) | (3.53) | (5.54) | (16.07) | |
Quick Ratio |
1.79 | 2.38 | 2.95 | 2.21 | |
Current Ratio |
2.90 | 3.58 | 4.31 | 3.37 | |
Net Debt/EBITDA |
(0.81) | (0.25) | (2.37) | 0.30 | |
Debt/Assets |
30.95% | 30.32% | 29.17% | 27.23% | |
Debt/Equity |
0.83 | 0.72 | 0.64 | 0.60 | |
Asset Turnover |
1.06 | 1.06 | 1.04 | 1.07 | |
Operating CF/Net income |
0.30 | (0.40) | 0.85 | 0.56 | |
Capex/Depreciation |
(1.03) | (2.63) | (0.83) | (0.99) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
9.64% | 9.79% | 7.26% | 9.32% | |
Selling, General and Administrative Expense of Revenue |
101.79% | 105.83% | 82.82% | 100.97% | |
Intangible Assets out of Total Assets |
0.11 | 0.11 | 0.10 | 0.10 | |
Share Based Compensation of Revenue |
14.24% | 17.02% | 12.08% | 15.93% | |
Graham Net Nets |
0.03 | 0.19 | 0.19 | 0.07 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(23.37%) | (72.39%) | (38.37%) | (11.92%) | |
Free Cash Flow Yield |
(9.67%) | (30.00%) | (19.02%) | (6.18%) | |
Revenue per Share |
0.70 | 0.73 | 0.99 | 0.79 | |
Operating CF per Share |
(0.07) | 0.11 | (0.13) | (0.14) | |
Capex per Share |
(0.03) | (0.05) | (0.04) | (0.04) | |
Free Cash Flow per Share |
(0.11) | 0.06 | (0.16) | (0.19) | |
Cash per Share |
0.70 | 0.80 | 0.76 | 0.90 | |
Shareholders Equity per Share |
1.04 | 1.20 | 1.38 | 1.40 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.04 | 1.20 | 1.38 | 1.40 | |
Free Cash Flow |
(6.90) | 4.18 | (10.42) | (11.90) | |
Working Capital |
78.96 | 88.98 | 101.42 | 97.09 | |
Capital Expenditures |
(2.20) | (3.06) | (2.40) | (2.81) | |
Net Current Asset Value |
7.14 | 16.56 | 28.81 | 30.59 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.06 | 0.04 | 0.06 | |
Net Profit Margin |
(34.98%) | (38.05%) | (15.03%) | (32.44%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
29.53 | 30.73 | 41.48 | 28.57 | |
Average Payables |
18.01 | 13.38 | 8.62 | 17.38 | |
Average Inventory |
40.97 | 37.15 | 37.64 | 42.52 | |
Average Assets |
193.75 | 194.97 | 203.84 | 204.76 | |
Average Common Equity |
82.68 | 91.27 | 100.11 | 97.05 |
Columns are period end dates